3OS0 Stock Chart & Stats
€5.94
€0.00(0.00%)
At close: 4:00 PM EDT
€5.94
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.94 - €6.39
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€12.51M
Enterprise Value€23.68
Total Cash (Recent Filing)€779.00K
Total Debt (Recent Filing)€7.56M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.48
Shares Outstanding15,979,411
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Acquisition And LeadershipAcquisition added a clinically de‑risked cell therapy and installed experienced leadership as CEO, strengthening operational capability to advance the lead program.
Clinical EfficacyLead dual-target CAR-T produced complete remissions and durable disease control in early patients while showing a favorable safety profile, supporting commercial potential in hard-to-treat cancers.
Regulatory PathwayPlanned registrational clinical trial for the lead CAR-T establishes a clear pathway toward potential regulatory approval and future commercialization.
Bears Say
Deprioritization Of Legacy AssetsLegacy oncology programs such as amezalpat and TPST‑1495 are being deprioritized and may stall without new financing or partnership support, reducing near-term asset value.
Development Funding GapAdvancement of legacy drug programs will require additional financing or partnerships, creating execution risk if new funding is not secured.
Shareholder DilutionTransaction structure causes existing shareholders to lose majority ownership and face substantial dilution, which can put downward pressure on the stock.
Tempest Therapeutics News
3OS0 FAQ
What was Tempest Therapeutics’s price range in the past 12 months?
Tempest Therapeutics lowest stock price was €5.94 and its highest was €6.38 in the past 12 months.
What is Tempest Therapeutics’s market cap?
Tempest Therapeutics’s market cap is €12.51M.
When is Tempest Therapeutics’s upcoming earnings report date?
Tempest Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 61 days.
How were Tempest Therapeutics’s earnings last quarter?
Tempest Therapeutics released its earnings results on Aug 13, 2026. The company reported -€0.294 earnings per share for the quarter, missing the consensus estimate of -€0.259 by -€0.035.
Is Tempest Therapeutics overvalued?
According to Wall Street analysts Tempest Therapeutics’s price is currently Overvalued.
Does Tempest Therapeutics pay dividends?
Tempest Therapeutics does not currently pay dividends.
What is Tempest Therapeutics’s EPS estimate?
Tempest Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tempest Therapeutics have?
Tempest Therapeutics has 15,979,411 shares outstanding.
What happened to Tempest Therapeutics’s price movement after its last earnings report?
Tempest Therapeutics reported an EPS of -€0.294 in its last earnings report, missing expectations of -€0.259. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tempest Therapeutics?
Currently, no hedge funds are holding shares in DE:3OS0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tempest Therapeutics
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.